The druggable genome: an update.

Annotating the druggable genome estimates the potential maximum size of the playing field for current small-molecule drug design but It does not consider biologicals or future breakthroughs in medicinal chemistry or biology.

[1]  Tim Hubbard.  Finishing the euchromatic sequence of the human genome , 2004 .

[2]  J. Drews.  Drug discovery: a historical perspective. , 2000, Science.

[3]  Cathy H. Wu,et al.  InterPro, progress and status in 2005 , 2004, Nucleic Acids Res..

[4]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[5]  Eric S. Lander.  Eric S. Lander , 2004, Nature Reviews Drug Discovery.

[6]  D. Ma,et al.  Kisspeptin directly stimulates gonadotropin-releasing hormone release via G protein-coupled receptor 54. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[7]  H. Schiöth,et al.  The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. , 2003, Molecular pharmacology.

[8]  Mark C. Fishman,et al.  Pharmaceuticals: A new grammar for drug discovery , 2005, Nature.

[9]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[10]  J. Drews,et al.  Drug Development: The role of innovation in drug development , 1997, Nature Biotechnology.

[11]  S. O’Rahilly,et al.  The GPR54 Gene as a Regulator of Puberty , 2003 .

[12]  G. Müller,et al.  Medicinal chemistry of target family-directed masterkeys. , 2003, Drug discovery today.

[13]  David Haussler,et al.  The UCSC Proteome Browser , 2004, Nucleic Acids Res..

[14]  X. Puente,et al.  Human and mouse proteases: a comparative genomic approach , 2003, Nature Reviews Genetics.

[15]  A L Hopkins,et al.  Target analysis: a priori assessment of druggability. , 2003, Ernst Schering Research Foundation workshop.

[16]  Richard Morphy,et al.  From magic bullets to designed multiple ligands. , 2004, Drug discovery today.

[17]  B. Roth,et al.  Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.

[18]  Serge Batalov,et al.  The promise of genomics to identify novel therapeutic targets , 2004, Expert opinion on therapeutic targets.